脑部放疗，上午比下午敏感许多！: z, G' w) x* z Z- x) M# Y
4 w# M5 ]9 O2 f, }9 {
- ^1 r( C, N- U2 NCancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.
% M. z% _5 Z- V% N2 [: V, {Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?/ b% ^) K) e$ _) _
Rahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.8 m$ [/ B4 o0 E2 ^
SourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.+ W8 s0 s5 v1 d# L
9 U6 N" n8 o) H8 v+ Y
Abstract- H [2 V0 d2 H! ]7 J- m) R$ y
BACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.: C5 J: a% |9 y' e: d1 @
) P0 J9 p+ ^! j @% ]METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.
% I4 r0 [, D8 b2 L# l
& D! G& I9 Z) S! ^, |2 A' URESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).
i; B% x: W2 E8 |8 j
0 p2 ]# \' \* _1 K! e, MCONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.
8 J8 W/ \) O. z+ d& X& } G% k1 A( h& g; x$ q0 J2 C
|
重启化疗后疼痛一直加重，是化疗无效
治疗经过如下：
Kras G12c 20.16%附带一个1.31%丰度的egfr21 PDL1阴性
靶向药的课题
依沃西用药后，该怎么办？
依沃西用药后，该怎么办？
我爸爸于2024年7月确诊肺鳞癌，整个治疗过程如附件里表格
妈妈与脑膜转奋战4年多，如今也成功
作者：李妮妮
2020年12月1号，妈妈在确诊晚期肺癌4年零10月，经历了化疗、一代靶向易
初诊必看：肿瘤患者诊断时最关心的10
作者：赵行
治不治
有人说，给父母看病治病天经地义，这是个值得讨论的话题吗？
我
盲试靶向药 29个月，治疗分享
时间：2025/1/27 盲试靶向药第29个月。
本月治疗方案：7080（14mg）。2024年11月底
) D/ J$ ^0 `9 K v" v, N7 o0 K
显身卡
